Articles from Coultreon Biopharma BV

Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer

Dr. Charuworn’s extensive immunology drug development experience will help accelerate the clinical development of Coultreon’s first-in-class SIK3 inhibitor COL-5671

By Coultreon Biopharma BV · Via GlobeNewswire · August 18, 2026